Cargando…
Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease
BACKGROUND: The cellular inflammatory pattern of nonsteroidal anti‐inflammatory drug–exacerbated respiratory disease (N‐ERD) is heterogeneous. However, data on the heterogeneity of non‐eosinophilic asthma (NEA) with aspirin hypersensitivity are scanty. By examination of N‐ERD patients based on clini...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009799/ https://www.ncbi.nlm.nih.gov/pubmed/36973957 http://dx.doi.org/10.1002/clt2.12235 |
_version_ | 1784906058882351104 |
---|---|
author | Mastalerz, Lucyna Celejewska‐Wójcik, Natalia Ćmiel, Adam Wójcik, Krzysztof Szaleniec, Joanna Hydzik‐Sobocińska, Karolina Tomik, Jerzy Sanak, Marek |
author_facet | Mastalerz, Lucyna Celejewska‐Wójcik, Natalia Ćmiel, Adam Wójcik, Krzysztof Szaleniec, Joanna Hydzik‐Sobocińska, Karolina Tomik, Jerzy Sanak, Marek |
author_sort | Mastalerz, Lucyna |
collection | PubMed |
description | BACKGROUND: The cellular inflammatory pattern of nonsteroidal anti‐inflammatory drug–exacerbated respiratory disease (N‐ERD) is heterogeneous. However, data on the heterogeneity of non‐eosinophilic asthma (NEA) with aspirin hypersensitivity are scanty. By examination of N‐ERD patients based on clinical data and eicosanoid biomarkers we aimed to identify NEA endotypes potentially guiding clinical management. METHODS: Induced sputum was collected from patients with N‐ERD. Sixty six patients (49.6% of 133 N‐ERD) with NEA were included in the hierarchical cluster analysis based on clinical and laboratory data. The quality of clustering was evaluated using internal cluster validation with different indices and a practical decision tree was proposed to simplify stratification of patients. RESULTS: The most frequent NEA pattern was paucigranulocytic (PGA; 75.8%), remaining was neutrophilic asthma (NA; 24.2%). Four clusters were identified. Cluster #3 included the highest number of NEA patients (37.9%) with severe asthma and PGA pattern (96.0%). Cluster #1 (24.2%) included severe only asthma, with a higher prevalence of NA (50%). Cluster #2 (25.8%) comprised well‐controlled mild or severe asthma (PGA; 76.5%). Cluster #4 contained only 12.1% patients with well‐controlled moderate asthma (PGA; 62.5%). Sputum prostaglandin D(2) levels distinguished cluster #1 from the remaining clusters with an area under the curve of 0.94. CONCLUSIONS: Among identified four NEA subtypes, clusters #3 and #1 represented N‐ERD patients with severe asthma but a different inflammatory signatures. All the clusters were discriminated by sputum PGD(2) levels, asthma severity, and age of patients. The heterogeneity of non‐eosinophilic N‐ERD suggests a need for novel targeted interventions. |
format | Online Article Text |
id | pubmed-10009799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100097992023-03-14 Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease Mastalerz, Lucyna Celejewska‐Wójcik, Natalia Ćmiel, Adam Wójcik, Krzysztof Szaleniec, Joanna Hydzik‐Sobocińska, Karolina Tomik, Jerzy Sanak, Marek Clin Transl Allergy Original Article BACKGROUND: The cellular inflammatory pattern of nonsteroidal anti‐inflammatory drug–exacerbated respiratory disease (N‐ERD) is heterogeneous. However, data on the heterogeneity of non‐eosinophilic asthma (NEA) with aspirin hypersensitivity are scanty. By examination of N‐ERD patients based on clinical data and eicosanoid biomarkers we aimed to identify NEA endotypes potentially guiding clinical management. METHODS: Induced sputum was collected from patients with N‐ERD. Sixty six patients (49.6% of 133 N‐ERD) with NEA were included in the hierarchical cluster analysis based on clinical and laboratory data. The quality of clustering was evaluated using internal cluster validation with different indices and a practical decision tree was proposed to simplify stratification of patients. RESULTS: The most frequent NEA pattern was paucigranulocytic (PGA; 75.8%), remaining was neutrophilic asthma (NA; 24.2%). Four clusters were identified. Cluster #3 included the highest number of NEA patients (37.9%) with severe asthma and PGA pattern (96.0%). Cluster #1 (24.2%) included severe only asthma, with a higher prevalence of NA (50%). Cluster #2 (25.8%) comprised well‐controlled mild or severe asthma (PGA; 76.5%). Cluster #4 contained only 12.1% patients with well‐controlled moderate asthma (PGA; 62.5%). Sputum prostaglandin D(2) levels distinguished cluster #1 from the remaining clusters with an area under the curve of 0.94. CONCLUSIONS: Among identified four NEA subtypes, clusters #3 and #1 represented N‐ERD patients with severe asthma but a different inflammatory signatures. All the clusters were discriminated by sputum PGD(2) levels, asthma severity, and age of patients. The heterogeneity of non‐eosinophilic N‐ERD suggests a need for novel targeted interventions. John Wiley and Sons Inc. 2023-03-13 /pmc/articles/PMC10009799/ /pubmed/36973957 http://dx.doi.org/10.1002/clt2.12235 Text en © 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Mastalerz, Lucyna Celejewska‐Wójcik, Natalia Ćmiel, Adam Wójcik, Krzysztof Szaleniec, Joanna Hydzik‐Sobocińska, Karolina Tomik, Jerzy Sanak, Marek Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease |
title | Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease |
title_full | Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease |
title_fullStr | Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease |
title_full_unstemmed | Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease |
title_short | Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease |
title_sort | non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009799/ https://www.ncbi.nlm.nih.gov/pubmed/36973957 http://dx.doi.org/10.1002/clt2.12235 |
work_keys_str_mv | AT mastalerzlucyna noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease AT celejewskawojciknatalia noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease AT cmieladam noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease AT wojcikkrzysztof noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease AT szaleniecjoanna noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease AT hydziksobocinskakarolina noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease AT tomikjerzy noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease AT sanakmarek noneosinophilicasthmainnonsteroidalantiinflammatorydrugexacerbatedrespiratorydisease |